| Identification | Back Directory | [Name]
(4R,12aS)-N-(2,4-Difluorobenzyl)-7-Methoxy-4-Methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-9-carboxaMide | [CAS]
1335210-35-9 | [Synonyms]
BNKY001-DL03
O-Methyl Dolutegravir
Dolutegravir O-Methyl Imp
Dolutegravir O-Methyl Impurity
Doultegravir O methyl impurity
(4R,12aS)-N-(2,4-Difluorobenzyl)-7-Methoxy-4-Methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-9-carboxaMide
(4R,12aS)-N-(2,4-difluorobenzyl)-7-methoxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-car boxamide
(4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-methoxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
2H-Pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, N-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-methoxy-4-methyl-6,8-dioxo-, (4R,12aS)-
Dolutegravir impurity 5/O-Methyl Dolutegravir/(4R,12aS)-N-[(2,4-Difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-methoxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide | [Molecular Formula]
C21H21F2N3O5 | [MDL Number]
MFCD29059073 | [MOL File]
1335210-35-9.mol | [Molecular Weight]
433.41 |
| Chemical Properties | Back Directory | [Boiling point ]
684.3±55.0 °C(Predicted) | [density ]
1.45±0.1 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Room Temperature | [pka]
10.70±0.40(Predicted) | [InChIKey]
MOSMLVZNRGURDI-BZNIZROVSA-N | [SMILES]
O1CC[C@@H](C)N2C(=O)C3=C(OC)C(=O)C(C(NCC4=CC=C(F)C=C4F)=O)=CN3C[C@]12[H] |
| Hazard Information | Back Directory | [Description]
Dolutegravir intermediate(1335210-35-9) is a new synthetic intermediate of Dolutegravir. Dolutegravir is an integrase inhibitor used to treat human immunodeficiency virus (HIV)-1 infection.
| [Uses]
(4R,12AS)-N-(2,4-Difluorobenzyl)-7-methoxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1'',2'':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide is an intermediate in the preparation of dolutegravir, an integrase inhibitor for HIV-1 infection therapy. | [Synthesis]
(3S,11aR)-3-methyl-6-(methyloxy)-5,7-dioxo-2,3,5,7,11,11a- hexahydro[1,3]oxazolo [3,2-a]pyrido[1,2-d]pyrazine-8-carboxylic acid (100 gm) and carbonyl dimidazole (78.89 gm) was suspended in acetonitrile (1000 mL). The mixture was heated to 75°C and stirred for 1 hour. The resulting solution was cooled to a temperature of 20°C and treated with 2,4- difluorobenzyl amine solution (55.2 gm was dissolved in 200 mL of acetonitrile). The reaction mixture was maintained for 2 hours, concentrated, and the compound was extracted with ethyl acetate (1000 mL). Isopropyl alcohol (500 mL) was added at 40°C, stirred the reaction mass for 30 minutes at a temperature of 50°C, and cooled the reaction mass to 25°C. The reaction mixture was maintained for 8 hours at the same temperature. The product O-Methyl Dolutegravir was collected by filtration and dried under vacuum (85 gm).
|
|
|